Silver Creek Pharmaceuticals
San Francisco, US · Delaware corporation
Silver Creek is a clinical-stage biopharmaceutical company developing targeted growth factor fusion protein therapies based on its Smart Growth Factor technology to treat damaged tissues. Its lead asset, scp776, delivers IGF1 cell survival functions to injury sites and is in clinical development for acute ischemic stroke, with preclinical activity in heart attack and kidney injury.</parameter> <parameter name="founders">[]
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$12.6M disclosed across 2 rounds · 2016–2022
▶$9.2MraisedFeb 2022 · 22 investors · PharmaceuticalsRule 506(b)
- Lakhmir ChawlaExecutive Officer
- James D. MarksDirector
- Mark AgneDirector
- Kris KuchenbeckerExecutive Officer
- Nick TaylorDirector
- Timothy ThrosbyExecutive Officer, Director
- Thomas J. MurtaghDirector
- Offering amount
- $25M
- Amount sold
- $9.2M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedDec 2016 · 13 investors · PharmaceuticalsRule 506(b)
- James MarksDirector
- Ross BreckenridgeExecutive Officer, Director
- Michael FairbanksDirector
- Ulrik NielsenDirector
- Tom MurtaghDirector
- Birgit SchoeberlExecutive Officer, Director
- Offering amount
- $19.8M
- Amount sold
- $3.4M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $221.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Silver Creek Pharmaceuticals do?
- Silver Creek is a clinical-stage biopharmaceutical company developing targeted growth factor fusion protein therapies based on its Smart Growth Factor technology to treat damaged tissues. Its lead asset, scp776, delivers IGF1 cell survival functions to injury sites and is in clinical development for acute ischemic stroke, with preclinical activity in heart attack and kidney injury.</parameter> <parameter name="founders">[]
- How much funding has Silver Creek Pharmaceuticals raised?
- Silver Creek Pharmaceuticals has disclosed $12.6M raised across 2 rounds.
- Where is Silver Creek Pharmaceuticals headquartered?
- Silver Creek Pharmaceuticals is headquartered in San Francisco, US.